FDA accelerated approval for Genmab’s bi-specific epcoritamab for 3L r/r follicular lymphoma

• Efficacy evaluated in EPCORE NHL-1 an open-label single-arm trial (n=127)

• ORR was 82% inc. 60% CR. median DOR was not reached. The 12-month Kaplan-Meier estimate for DOR was 68.4%

• PMR to verify the clinical benefit is an ongoing Phase 3 trial (NCT05409066) evaluating rituximab + lenalidomide alone vs. in combination with epcoritamab in patients with 2L r/r FL. This study is currently >95% enrolled; PFS is the primary endpoint

European Approval for Takeda's FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

• Approval is based on Phase 3 FRESCO-2 trial of FRUZAQLA (fruquintinib) + BSC vs. PBO in patients with previously treated mCRC

• Median OS was 7·4 months (95% CI 6·7–8·2) in the fruquintinib group versus 4·8 months (4·0–5·8) in PBO (HR 0·66, 95% CI 0·55–0·80; p<0·0001)

• Approval follows Nov 2023 FDA approval for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens

FDA grants accelerated approval to Krazati (adagrasib) + cetuximab for KRAS G12C-mutated CRC

• Efficacy was evaluated in KRYSTAL-1, a single-arm expansion cohort trial (n=94)

• ORR was 34% (all partial responses; mDOR was 5.8 months.

• 31% of responding patients had a DOR of at least 6 months.

• sNDA granted priority review and breakthrough therapy designation

FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer

• While a statistically significant improvement in PFS was observed in the overall population for durvalumab with carboplatin plus paclitaxel compared to carboplatin and paclitaxel alone, the improvement in the overall population was primarily attributed to patients with dMMR tumors based on an exploratory analysis by tumor MMR status.

• In 95 patients with dMMR tumors, median PFS was not reached (NR) (95% CI: NR, NR) in the durvalumab arm and was 7 months (95% CI: 6.7, 14.8) in the placebo arm (hazard ratio: 0.42 [95% CI: 0.22, 0.80]). Overall survival, an additional efficacy outcome measure, was immature at the PFS analysis.

• Approval granted for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)

FDA Approves Breyanzi CAR T Cell Therapy for R/R  Mantle Cell Lymphoma

• Approval based on the MCL cohort (n=68) of TRANSCEND NHL 001, which enrolled adults with who had previously received at least two or more prior lines of therapy, including a BTK inhibitor

• Per label, ORR was 85.3%, with 67.6% achieving a complete response (CR). Responses were rapid and durable with a median time to response of one month (range: 0.7-3) and median duration of response of 13.3 months, with a median follow-up of 22.2 months

• Results from the primary analysis published in the Journal of Clinical Oncology (JCO) (n=83; DL1 + DL2) showed an ORR of 83.1% , with CR rate of 72.3%. Median duration of response was 15.7 months and PFS was 15.3 months

European Commission Approve Opdivo (nivolumab)-Chemo Combination for First-Line Unresectable or Metastatic Urothelial Carcinoma

• Approval based on CheckMate -901, the first Phase 3 trial in this patient population with an immunotherapy-chemotherapy combination to demonstrate survival benefit vs. chemotherapy

• With a median follow up of approx. 33 months, Opdivo in combination with cisplatin and gemcitabine provided a median OS of 21.7 months vs. 18.9 months with cisplatin-gemcitabine alone (HR: 0.78; 95% CI: 0.63, 0.96; p=0.0171)

• Becomes first concurrent immunotherapy-chemotherapy combination approved for this patient population in the European Union

First FDA approval of a targeted therapy for pediatric patients < 12 years of age with RET alterations.

Accelerated approval for selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients 2years of age and older with the following:

• Advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy;

• Advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate);

• Locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

FDA grants accelerated approval to tarlatamab for extensive stage small cell lung cancer

• Efficacy was evaluated in 99 patients with relapsed/refractory ES-SCLC with disease progression following platinum-based chemotherapy

• ORR 40% with median DOR 9.7 months (range 2.7, 20.7+). Of the 69 patients with available data regarding platinum sensitivity status, the ORR was 52% in 27 patients with platinum-resistant SCLC (defined as progression < 90 days after last dose of platinum therapy) and 31% in 42 patients with platinum-sensitive SCLC (defined as progression ≥ 90 days after last dose of platinum therapy).

• BLA reviewed utilized Project Orbis (FDA + Brazil's ANVISA, Health Canada, Israel’s Ministry of Health and the UK's MHRA). FDA reviewed under RTOR, with approval coming  1 month ahead of the goal date.